Real-world impact and effectiveness assessment of the quadrivalent HPV vaccine: a systematic review of study designs and data sources

References

• WHO. Human papillomavirus vaccines: WHO position paper, May 2017. Contract No1:19.
   Google Scholar
• Harper DM, DeMars LR. HPV vaccines - A review of the first decade. Gynecol Oncol. 2017;146(1):196–204.
   PubMed Web of Science ®Google Scholar
• FDA. Human papillomavirus vaccine. 2018 Available from: https://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm172678.htm.
   Google Scholar
• Qiao YL, Wu T, Li RC, et al. Efficacy, safety, and immunogenicity of an escherichia coli-produced bivalent human papillomavirus vaccine: an interim analysis of a randomized clinical trial. J Natl Cancer Inst. 2020;112(2):145–153.
   PubMedGoogle Scholar
• Hanquet G, Valenciano M, Simondon F, et al. Vaccine effects and impact of vaccination programmes in post-licensure studies. Vaccine. 2013;31(48):5634–5642.
   PubMed Web of Science ®Google Scholar
• Halloran ME, Struchiner CJ. Study designs for dependent happenings. Epidemiology. 1991;2(5):331–338.
   PubMed Web of Science ®Google Scholar
• Oliveira CR, Niccolai LM. Monitoring HPV vaccine impact on cervical disease: status and future directions for the era of cervical cancer elimination. Prev Med. 2021;144:106363.
   PubMed Web of Science ®Google Scholar
• Garland SM, Kjaer SK, Munoz N, et al. Impact and effectiveness of the quadrivalent human papillomavirus vaccine: a systematic review of 10 years of real-world experience. Clin Infect Dis. 2016;63(4):519–527.
   PubMed Web of Science ®Google Scholar
• Derkay CS, Wiatrak B. Recurrent respiratory papillomatosis: a review. Laryngoscope. 2008;118(7):1236–1247.
   PubMed Web of Science ®Google Scholar
• Ouzzani M, Hammaday H, Federowicx Z, et al. Rayyan - a web and mobile app for systematic reviews. Syst Rev. 2016;5:210.
   PubMed Web of Science ®Google Scholar
• Cummings T, Zimet GD, Brown D, et al. Reduction of HPV infections through vaccination among at-risk urban adolescents. Vaccine. 2012;30(37):5496–5499.
   PubMed Web of Science ®Google Scholar
• Powell SE, Hariri S, Steinau M, et al. Impact of human papillomavirus (HPV) vaccination on HPV 16/18-related prevalence in precancerous cervical lesions. Vaccine. 2012;31(1):109–113.
   PubMed Web of Science ®Google Scholar
• Schlecht NF, Burk RD, Nucci-Sack A, et al. Cervical, anal and oral HPV in an adolescent inner-city health clinic providing free vaccinations. PLoS One. 2012;7(5):e37419.
   PubMed Web of Science ®Google Scholar
• Swedish KA, Factor SH, Goldstone SE. Prevention of recurrent high-grade anal neoplasia with quadrivalent human papillomavirus vaccination of men who have sex with men: a nonconcurrent cohort study. Clin Infect Dis. 2012;54(7):891–898.
   PubMed Web of Science ®Google Scholar
• Tabrizi SN, Brotherton JM, Kaldor JM, et al. Fall in human papillomavirus prevalence following a national vaccination program. J Infect Dis. 2012;206(11):1645–1651.
   PubMed Web of Science ®Google Scholar
• Blomberg M, Dehlendorff C, Munk C, et al. Strongly decreased risk of genital warts after vaccination against human papillomavirus: nationwide follow-up of vaccinated and unvaccinated girls in Denmark. Clin Infect Dis. 2013;57(7):929–934.
   PubMed Web of Science ®Google Scholar
• Gertig DM, Brotherton JM, Budd AC, et al. Impact of a population-based HPV vaccination program on cervical abnormalities: a data linkage study. BMC Med. 2013;11:227.
   PubMed Web of Science ®Google Scholar
• Leval A, Herweijer E, Ploner A, et al. Quadrivalent human papillomavirus vaccine effectiveness: a Swedish national cohort study. J Natl Cancer Inst. 2013;105(7):469–474.
   PubMedGoogle Scholar
• Baldur-Felskov B, Dehlendorff C, Junge J, et al. Incidence of cervical lesions in Danish women before and after implementation of a national HPV vaccination program. Cancer Causes Control. 2014;25(7):915–922.
   PubMed Web of Science ®Google Scholar
• Crowe E, Pandeya N, Brotherton JM, et al. Effectiveness of quadrivalent human papillomavirus vaccine for the prevention of cervical abnormalities: case-control study nested within a population based screening programme in Australia. BMJ. 2014;348:g1458.
   PubMed Web of Science ®Google Scholar
• Delere Y, Remschmidt C, Leuschner J, et al. Human Papillomavirus prevalence and probable first effects of vaccination in 20 to 25 year-old women in Germany: a population-based cross-sectional study via home-based self-sampling. BMC Infect Dis. 2014;14:87.
   PubMed Web of Science ®Google Scholar
• Herweijer E, Leval A, Ploner A, et al. Association of varying number of doses of quadrivalent human papillomavirus vaccine with incidence of condyloma. JAMA. 2014;311(6):597–603.
   PubMed Web of Science ®Google Scholar
• Mahmud SM, Kliewer EV, Lambert P, et al. Effectiveness of the quadrivalent human papillomavirus vaccine against cervical dysplasia in Manitoba, Canada. J Clin Oncol. 2014;32(5):438–443.
   PubMed Web of Science ®Google Scholar
• Swedish KA, Goldstone SE. Prevention of anal condyloma with quadrivalent human papillomavirus vaccination of older men who have sex with men. PLoS One. 2014;9(4):e93393.
   PubMed Web of Science ®Google Scholar
• Tabrizi SN, Brotherton JM, Stevens MP, et al. HPV genotype prevalence in Australian women undergoing routine cervical screening by cytology status prior to implementation of an HPV vaccination program. J Clin Virol. 2014;60(3):250–256.
   PubMed Web of Science ®Google Scholar
• Blomberg M, Dehlendorff C, Sand C, et al. Dose-related differences in effectiveness of human papillomavirus vaccination against genital warts: a nationwide study of 550,000 young girls. Clin Infect Dis. 2015;61(5):676–682.
   PubMed Web of Science ®Google Scholar
• Brotherton JML, Malloy M, Budd AC, et al. Effectiveness of less than three doses of quadrivalent human papillomavirus vaccine against cervical intraepithelial neoplasia when administered using a standard dose spacing schedule: observational cohort of young women in Australia. Papillomavirus Res. 2015;1:59–73.
   Web of Science ®Google Scholar
• Hariri S, Bennett NM, Niccolai LM, et al. Reduction in HPV 16/18-associated high grade cervical lesions following HPV vaccine introduction in the United States - 2008-2012. Vaccine. 2015;33(13):1608–1613.
   PubMed Web of Science ®Google Scholar
• Kahn JA, Rudy BJ, Xu J, et al. Behavioral, immunologic, and virologic correlates of oral human papillomavirus infection in HIV-infected youth. Sex Transm Dis. 2015;42(5):246–252.
   PubMed Web of Science ®Google Scholar
• Arbyn M, Broeck DV, Benoy I, et al. Surveillance of effects of HPV vaccination in Belgium. Cancer Epidemiol. 2016;41:152–158.
   PubMed Web of Science ®Google Scholar
• Franceschi S, Chantal Umulisa M, Tshomo U, et al. Urine testing to monitor the impact of HPV vaccination in Bhutan and Rwanda. Int J Cancer. 2016;139(3):518–526.
   PubMed Web of Science ®Google Scholar
• Herweijer E, Sundstrom K, Ploner A, et al. Quadrivalent HPV vaccine effectiveness against high-grade cervical lesions by age at vaccination: a population-based study. Int J Cancer. 2016;138(12):2867–2874.
   PubMed Web of Science ®Google Scholar
• Hofstetter AM, Ompad DC, Stockwell MS, et al. Human papillomavirus vaccination and cervical cytology outcomes among urban low-income minority females. JAMA Pediatr. 2016;170(5):445–452.
   PubMed Web of Science ®Google Scholar
• Kim J, Bell C, Sun M, et al. Effect of human papillomavirus vaccination on cervical cancer screening in Alberta. CMAJ. 2016;188(12):E281–8.
   PubMed Web of Science ®Google Scholar
• Markowitz LE, Liu G, Hariri S, et al. Prevalence of HPV after introduction of the vaccination program in the United States. Pediatrics. 2016;137(3):e20151968.
   PubMed Web of Science ®Google Scholar
• Schlecht NF, Diaz A, Shankar V, et al. Risk of delayed human papillomavirus vaccination in inner-city adolescent women. J Infect Dis. 2016;214(12):1952–1960.
   PubMed Web of Science ®Google Scholar
• Ozawa N, Ito K, Tase T, et al. Beneficial effects of human papillomavirus vaccine for prevention of cervical abnormalities in Miyagi, Japan. Tohoku J Exp Med. 2016;240(2):147–151.
   PubMed Web of Science ®Google Scholar
• Han JJ, Beltran TH, Song JW, et al. Prevalence of genital human papillomavirus infection and human papillomavirus vaccination rates among US adult men: National Health and Nutrition Examination Survey (NHANES) 2013-2014. JAMA Oncol. 2017;3(6):810–816.
   PubMed Web of Science ®Google Scholar
• Heard I, Tondeur L, Arowas L, et al. Effectiveness of human papillomavirus vaccination on prevalence of vaccine genotypes in young sexually active women in France. J Infect Dis. 2017;215(5):757–763.
   PubMed Web of Science ®Google Scholar
• Hirth JM, Chang M, Resto VA. HPV Study Group. Prevalence of oral human papillomavirus by vaccination status among young adults (18-30 years old). Vaccine. 2017;35(27):3446–3451.
   PubMed Web of Science ®Google Scholar
• Navarro-Illana E, Lopez-Lacort M, Navarro-Illana P, et al. Effectiveness of HPV vaccines against genital warts in women from Valencia, Spain. Vaccine. 2017;35(25):3342–3346.
   PubMed Web of Science ®Google Scholar
• Ozawa N, Ito K, Tase T, et al. Lower incidence of cervical intraepithelial neoplasia among young women with human papillomavirus vaccination in Miyagi, Japan. Tohoku J Exp Med. 2017;243(4):329–334.
   PubMed Web of Science ®Google Scholar
• Perkins RB, Lin M, Wallington SF, et al. Impact of number of human papillomavirus vaccine doses on genital warts diagnoses among a national cohort of U.S. adolescents. Sex Transm Dis. 2017;44(6):365–370.
   PubMed Web of Science ®Google Scholar
• Tanaka H, Shirasawa H, Shimizu D, et al. Preventive effect of human papillomavirus vaccination on the development of uterine cervical lesions in young Japanese women. J Obstet Gynaecol Res. 2017;43(10):1597–1601.
   PubMed Web of Science ®Google Scholar
• Carozzi F, Puliti D, Ocello C, et al. Monitoring vaccine and non-vaccine HPV type prevalence in the post-vaccination era in women living in the Basilicata region, Italy. BMC Infect Dis. 2018;18(1):38.
   PubMedGoogle Scholar
• Chandler E, Ding L, Gorbach P, et al. Epidemiology of any and vaccine-type anogenital human papillomavirus among 13-26-year-old young men after HPV vaccine introduction. J Adolesc Health. 2018;63(1):43–49.
   PubMed Web of Science ®Google Scholar
• Chaturvedi AK, Graubard BI, Broutian T, et al. Effect of prophylactic Human Papillomavirus (HPV) vaccination on oral HPV infections among young adults in the United States. J Clin Oncol. 2018;36(3):262–267.
   PubMed Web of Science ®Google Scholar
• Cocchio S, Bertoncello C, Baldovin T, et al. Self-reported genital warts among sexually-active university students: a cross-sectional study. BMC Infect Dis. 2018;18(1):41.
   PubMedGoogle Scholar
• Dehlendorff C, Sparén P, Baldur-Felskov B, et al. Effectiveness of varying number of doses and timing between doses of quadrivalent HPV vaccine against severe cervical lesions. Vaccine. 2018;36(43):6373–6378.
   PubMed Web of Science ®Google Scholar
• Garland SM, Cornall AM, Brotherton JML, et al. Final analysis of a study assessing genital human papillomavirus genoprevalence in young Australian women, following eight years of a national vaccination program. Vaccine. 2018;36(23):3221–3230.
   PubMed Web of Science ®Google Scholar
• Goggin P, Sauvageau C, Gilca V, et al. Low prevalence of vaccine-type HPV infections in young women following the implementation of a school-based and catch-up vaccination in Quebec, Canada. Hum Vaccin Immunother. 2018;14(1):118–123.
   PubMed Web of Science ®Google Scholar
• Hariri S, Schuler MS, Naleway AL, et al. Human papillomavirus vaccine effectiveness against incident genital warts among female health-plan enrollees, United States. Am J Epidemiol. 2018;187(2):298–305.
   PubMed Web of Science ®Google Scholar
• Jeannot E, Viviano M, de Pree C, et al. Prevalence of vaccine type infections in vaccinated and non-vaccinated young women: HPV-IMPACT, a self-sampling study. Int J Environ Res Public Health. 2018;15:7.
   Web of Science ®Google Scholar
• Saccucci M, Franco EL, Ding L, et al. Non-vaccine-type human papillomavirus prevalence after vaccine introduction: no evidence for type replacement but evidence for cross-protection. Sex Transm Dis. 2018;45(4):260–265.
   PubMed Web of Science ®Google Scholar
• Silverberg MJ, Leyden WA, Lam JO, et al. Effectiveness of catch-up human papillomavirus vaccination on incident cervical neoplasia in a US health-care setting: a population-based case-control study. Lancet Child Adolesc Health. 2018;2(10):707–714.
   PubMedGoogle Scholar
• Vänskä S, Söderlund-Strand A, Uhnoo I, et al. Estimating effectiveness of HPV vaccination against HPV infection from post-vaccination data in the absence of baseline data. Vaccine. 2018;36(23):3239–3246.
   PubMed Web of Science ®Google Scholar
• Willows K, Bozat-Emre S, Righolt CH, et al. Early evidence of the effectiveness of the human papillomavirus vaccination program against anogenital warts in Manitoba, Canada: a registry cohort study. Sex Transm Dis. 2018;45(4):254–259.
   PubMed Web of Science ®Google Scholar
• Zeybek B, Lin YL, Kuo YF, et al. The impact of varying numbers of quadrivalent human papillomavirus vaccine doses on anogenital warts in the United States: a database study. J Low Genit Tract Dis. 2018;22(3):189–194.
   PubMed Web of Science ®Google Scholar
• Basu P, Muwonge R, Bhatla N, et al. Two-dose recommendation for human papillomavirus vaccine can be extended up to 18 years – updated evidence from Indian follow-up cohort study. Papillomavirus Res. 2019;7:75–81.
   PubMed Web of Science ®Google Scholar
• Batmunkh T, Von Mollendorf C, Tulgaa K, et al. HPV genoprevalence and HPV knowledge in young women in Mongolia, five years following a pilot 4vHPV vaccination campaign. Papillomavirus Res. 2019;8:100175.
   PubMed Web of Science ®Google Scholar
• Brotherton JM, Hawkes D, Sultana F, et al. Age-specific HPV prevalence among 116,052 women in Australia’s renewed cervical screening program: a new tool for monitoring vaccine impact. Vaccine. 2019;37(3):412–416.
   PubMed Web of Science ®Google Scholar
• Brouwer AF, Eisenberg MC, Carey TE, et al. Multisite HPV infections in the United States (NHANES 2003-2014): an overview and synthesis. Prev Med. 2019;123:288–298.
   PubMed Web of Science ®Google Scholar
• Castillo A, Osorio JC, Fernandez A, et al. Effect of vaccination against oral HPV-16 infection in high school students in the city of Cali, Colombia. Papillomavirus Res. 2019;7:112–117.
   PubMed Web of Science ®Google Scholar
• Castle PE, Xie X, Xue X, et al. Impact of human papillomavirus vaccination on the clinical meaning of cervical screening results. Prev Med. 2019;118:44–50.
   PubMed Web of Science ®Google Scholar
• Enerly E, Flingtorp R, Christiansen IK, et al. An observational study comparing HPV prevalence and type distribution between HPV-vaccinated and -unvaccinated girls after introduction of school-based HPV vaccination in Norway. PLoS One. 2019;14(10):e0223612.
   PubMed Web of Science ®Google Scholar
• Feder MA, Kulasingam SL, Kiviat NB, et al. Correlates of human papillomavirus vaccination and association with HPV-16 and HPV-18 DNA detection in young women. J Womens Health (Larchmt). 2019;28(10):1428–1435.
   PubMed Web of Science ®Google Scholar
• Johnson Jones ML, Gargano JW, Powell M, et al. Effectiveness of 1, 2, AND 3 human papillomavirus vaccine doses against HPV-16/18 positive high-grade cervical lesions. Am J Epidemiol. 2019; 189 (4): 265–276. .
   Web of Science ®Google Scholar
• Latsuzbaia A, Arbyn M, Tapp J, et al. Effectiveness of bivalent and quadrivalent human papillomavirus vaccination in Luxembourg. Cancer Epidemiol. 2019;63:101593.
   PubMed Web of Science ®Google Scholar
• Righolt CH, Bozat-Emre S, Mahmud SM. Effectiveness of school-based and high-risk human papillomavirus vaccination programs against cervical dysplasia in Manitoba, Canada. Int J Cancer. 2019;145:671–677.
   PubMed Web of Science ®Google Scholar
• Sonawane K, Nyitray AG, Nemutlu GS, et al. Prevalence of human papillomavirus infection by number of vaccine doses among US women. JAMA Network Open. 2019;2(12):e1918571.
   PubMed Web of Science ®Google Scholar
• Wright TC, Parvu V, Stoler MH, et al. HPV infections and cytologic abnormalities in vaccinated women 21–34 years of age: results from the baseline phase of the onclarity trial. Gynecol Oncol. 2019;153(2):259–265.
   PubMed Web of Science ®Google Scholar
• Innes CR, Williman JA, Simcock BJ, et al. Impact of human papillomavirus vaccination on rates of abnormal cervical cytology and histology in young New Zealand women. N Z Med J. 2020;133(1508):72–84.
   PubMed Web of Science ®Google Scholar
• Markowitz LE, Naleway AL, Klein NP, et al. Human papillomavirus vaccine effectiveness against HPV infection: evaluation of one, two, and three doses. J Infect Dis. 2020;221(6):910–918.
   PubMed Web of Science ®Google Scholar
• Racey CS, Albert A, Donken R, et al. Cervical intraepithelial Neoplasia rates in British Columbia Women: a population-level data linkage evaluation of the school-based HPV immunization program. J Infect Dis. 2020;221(1):81–90.
   PubMed Web of Science ®Google Scholar
• Rodriguez AM, Zeybek B, Vaughn M, et al. Comparison of the long-term impact and clinical outcomes of fewer doses and standard doses of human papillomavirus vaccine in the United States: a database study. Cancer. 2020;126:1656–1667.
   PubMed Web of Science ®Google Scholar
• Seong J, Ryou S, Yoo M, et al. Status of HPV vaccination among HPV-infected women aged 20-60 years with abnormal cervical cytology in South Korea: a multicenter, retrospective study. J Gynecol Oncol. 2020;31(1):e4.
   PubMed Web of Science ®Google Scholar
• Shilling H, Murray G, Brotherton JML, et al. Monitoring human papillomavirus prevalence among young Australian women undergoing routine chlamydia screening. Vaccine. 2020;38(5):1186–1193.
   PubMed Web of Science ®Google Scholar
• Verdoodt F, Dehlendorff C, Kjaer SK. Dose-related effectiveness of quadrivalent human papillomavirus vaccine against cervical intraepithelial Neoplasia: a Danish nationwide cohort study. Clin Infect Dis. 2020;70(4):608–614.
   PubMed Web of Science ®Google Scholar
• Fairley CK, Hocking JS, Gurrin LC, et al. Rapid decline in presentations of genital warts after the implementation of a national quadrivalent human papillomavirus vaccination programme for young women. Sex Transm Infect. 2009;85(7):499–502.
   PubMed Web of Science ®Google Scholar
• Brotherton JM, Fridman M, May CL, et al. Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study. Lancet. 2011;377(9783):2085–2092.
   PubMed Web of Science ®Google Scholar
• Donovan B, Franklin N, Guy R, et al. Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data. Lancet Infect Dis. 2011;11(1):39–44.
   PubMed Web of Science ®Google Scholar
• Oliphant J, Perkins N. Impact of the human papillomavirus (HPV) vaccine on genital wart diagnoses at Auckland sexual health services. N Z Med J. 2011;124(1339):51–58.
   PubMedGoogle Scholar
• Read TR, Hocking JS, Chen MY, et al. The near disappearance of genital warts in young women 4 years after commencing a national human papillomavirus (HPV) vaccination programme. Sex Transm Infect. 2011;87(7):544–547.
   PubMed Web of Science ®Google Scholar
• Bauer HM, Wright G, Chow J. Evidence of human papillomavirus vaccine effectiveness in reducing genital warts: an analysis of California public family planning administrative claims data, 2007-2010. Am J Public Health. 2012;102(5):833–835.
   PubMed Web of Science ®Google Scholar
• Kahn JA, Brown DR, Ding L, et al. Vaccine-type human papillomavirus and evidence of herd protection after vaccine introduction. Pediatrics. 2012;130(2):e249–56.
   PubMed Web of Science ®Google Scholar
• Leval A, Herweijer E, Arnheim-Dahlstrom L, et al. Incidence of genital warts in Sweden before and after quadrivalent human papillomavirus vaccine availability. J Infect Dis. 2012;206(6):860–866.
   PubMed Web of Science ®Google Scholar
• Ali H, Donovan B, Wand H, et al. Genital warts in young Australians five years into national human papillomavirus vaccination programme: national surveillance data. BMJ. 2013;346:f2032.
   PubMed Web of Science ®Google Scholar
• Ali H, Guy RJ, Wand H, et al. Decline in in-patient treatments of genital warts among young Australians following the national HPV vaccination program. BMC Infect Dis. 2013;13:140.
   PubMed Web of Science ®Google Scholar
• Baandrup L, Blomberg M, Dehlendorff C, et al. Significant decrease in the incidence of genital warts in young Danish women after implementation of a national human papillomavirus vaccination program. Sex Transm Dis. 2013;40(2):130–135.
   PubMed Web of Science ®Google Scholar
• Flagg EW, Schwartz R, Weinstock H. Prevalence of anogenital warts among participants in private health plans in the United States, 2003-2010: potential impact of human papillomavirus vaccination. Am J Public Health. 2013;103(8):1428–1435.
   PubMed Web of Science ®Google Scholar
• Jemal A, Simard EP, Dorell C, et al. Annual report to the nation on the status of cancer, 1975–2009, featuring the burden and trends in Human Papillomavirus (HPV)–associated cancers and HPV vaccination coverage levels. J Natl Cancer Inst. 2013;105(3):175–201.
   PubMed Web of Science ®Google Scholar
• Markowitz LE, Hariri S, Lin C, et al. Reduction in Human Papillomavirus (HPV) prevalence among young women following HPV vaccine introduction in the United States, national health and nutrition examination surveys, 2003–2010. J Infect Dis. 2013;208(3):385–393.
   PubMed Web of Science ®Google Scholar
• Mikolajczyk RT, Kraut AA, Horn J, et al. Changes in incidence of anogenital warts diagnoses after the introduction of human papillomavirus vaccination in Germany-an ecologic study. Sex Transm Dis. 2013;40(1):28–31.
   PubMed Web of Science ®Google Scholar
• Niccolai LM, Julian PJ, Meek JI, et al. Declining rates of high-grade cervical lesions in young women in Connecticut, 2008-2011. Cancer Epidemiol Biomarkers Prev. 2013;22(8):1446–1450.
   PubMed Web of Science ®Google Scholar
• Nsouli-Maktabi H, Ludwig SL, Yerubandi UD, et al. Incidence of genital warts among U.S. service members before and after the introduction of the quadrivalent human papillomavirus vaccine. Msmr. 2013;20(2):17–20.
   PubMedGoogle Scholar
• Baldur-Felskov B, Dehlendorff C, Munk C, et al. Early impact of human papillomavirus vaccination on cervical neoplasia–nationwide follow-up of young Danish women. J Natl Cancer Inst. 2014;106(3):djt460.
   PubMed Web of Science ®Google Scholar
• Harrison C, Britt H, Garland S, et al. Decreased management of genital warts in young women in Australian general practice post introduction of national HPV vaccination program: results from a nationally representative cross-sectional general practice study. PLoS One. 2014;9(9):e105967.
   PubMed Web of Science ®Google Scholar
• Liu B, Donovan B, Brotherton JM, et al. Genital warts and chlamydia in Australian women: comparison of national population-based surveys in 2001 and 2011. Sex Transm Infect. 2014;90(7):532–537.
   PubMed Web of Science ®Google Scholar
• Merckx M, Benoy I, Meys J, et al. High frequency of genital human papillomavirus infections and related cervical dysplasia in adolescent girls in Belgium. Eur J Cancer Prev. 2014;23(4):288–293.
   PubMed Web of Science ®Google Scholar
• Sando N, Kofoed K, Zachariae C, et al. A reduced national incidence of anogenital warts in young Danish men and women after introduction of a national quadrivalent human papillomavirus vaccination programme for young women–an ecological study. Acta Derm Venereol. 2014;94(3):288–292.
   PubMed Web of Science ®Google Scholar
• Söderlund-Strand A, Uhnoo I, Dillner J. Change in population prevalences of human papillomavirus after initiation of vaccination: the high-throughput HPV monitoring study. Cancer Epidemiol Biomarkers Prev. 2014;23(12):2757–2764.
   PubMed Web of Science ®Google Scholar
• Wilson N, Morgan J, Baker MG. Evidence for effectiveness of a national HPV vaccination programme: national prescription data from New Zealand. Sex Transm Infect. 2014;90(2):103.
   PubMed Web of Science ®Google Scholar
• Wilson AR, Welch RJ, Hashibe M, et al. Surveillance of human papilloma virus using reference laboratory data for the purpose of evaluating vaccine impact. Online J Public Health Inform. 2014;6(3):e194.
   PubMedGoogle Scholar
• Baldur-Felskov B, Munk C, Nielsen TS, et al. Trends in the incidence of cervical cancer and severe precancerous lesions in Denmark, 1997-2012. Cancer Causes Control. 2015;26(8):1105–1116.
   PubMed Web of Science ®Google Scholar
• Brotherton JM, Saville AM, May CL, et al. Human papillomavirus vaccination is changing the epidemiology of high-grade cervical lesions in Australia. Cancer Causes Control. 2015;26(6):953–954.
   PubMed Web of Science ®Google Scholar
• Chow EP, Read TR, Wigan R, et al. Ongoing decline in genital warts among young heterosexuals 7 years after the Australian human papillomavirus (HPV) vaccination programme. Sex Transm Infect. 2015;91(3):214–219.
   PubMed Web of Science ®Google Scholar
• Dickson EL, Vogel RI, Luo X, et al. Recent trends in type-specific HPV infection rates in the United States. Epidemiol Infect. 2015;143(5):1042–1047.
   PubMed Web of Science ®Google Scholar
• Dunne EF, Naleway A, Smith N, et al. Reduction in human papillomavirus vaccine type prevalence among young women screened for cervical cancer in an integrated US healthcare delivery system in 2007 and 2012-2013. J Infect Dis. 2015;212(12):1970–1975.
   PubMed Web of Science ®Google Scholar
• Hariri S, Johnson ML, Bennett NM, et al. Population-based trends in high-grade cervical lesions in the early human papillomavirus vaccine era in the United States. Cancer. 2015;121(16):2775–2781.
   PubMed Web of Science ®Google Scholar
• Smith MA, Liu B, McIntyre P, et al. Fall in genital warts diagnoses in the general and indigenous Australian population following implementation of a national human papillomavirus vaccination program: analysis of routinely collected national hospital data. J Infect Dis. 2015;211(1):91–99.
   PubMed Web of Science ®Google Scholar
• Berenson AB, Laz TH, Rahman M. Reduction in vaccine-type human papillomavirus prevalence among women in the United States, 2009-2012. J Infect Dis. 2016;214(12):1961–1964.
   PubMed Web of Science ®Google Scholar
• Bollerup S, Baldur-Felskov B, Blomberg M, et al. Significant reduction in the incidence of genital warts in young men 5 years into the danish human papillomavirus vaccination program for girls and women. Sex Transm Dis. 2016;43(4):238–242.
   PubMed Web of Science ®Google Scholar
• Brotherton JM, Gertig DM, May C, et al. HPV vaccine impact in Australian women: ready for an HPV-based screening program. Med J Aust. 2016;204(5):184–e1.
   PubMed Web of Science ®Google Scholar
• Flagg EW, Torrone EA, Weinstock H. Ecological association of human papillomavirus vaccination with cervical Dysplasia prevalence in the United States, 2007-2014. Am J Public Health. 2016;106(12):2211–2218.
   PubMed Web of Science ®Google Scholar
• Guerra FM, Rosella LC, Dunn S, et al. Early impact of Ontario’s human papillomavirus (HPV) vaccination program on anogenital warts (AGWs): a population-based assessment. Vaccine. 2016;34(39):4678–4683.
   PubMed Web of Science ®Google Scholar
• Judlin P, Jacquard AC, Carcopino X, et al. Potential impact of the human papillomavirus vaccine on the incidence proportion of genital warts in French women (EFFICAE study): a multicentric prospective observational study. Sex Health. 2016;13(1):49–54.
   PubMed Web of Science ®Google Scholar
• Smith MA, Liu B, McIntyre P, et al. Trends in genital warts by socioeconomic status after the introduction of the national HPV vaccination program in Australia: analysis of national hospital data. BMC Infect Dis. 2016;16:52.
   PubMed Web of Science ®Google Scholar
• Tarney CM, Klaric J, Beltran T, et al. Prevalence of human papillomavirus in self-collected cervicovaginal Swabs in young women in the United States Between 2003 and 2012. Obstet Gynecol. 2016;128(6):1241–1247.
   PubMed Web of Science ®Google Scholar
• Ali H, McManus H, O’Connor CC, et al. Human papillomavirus vaccination and genital warts in young Indigenous Australians: national sentinel surveillance data. Med J Aust. 2017;206(5):204–209.
   PubMed Web of Science ®Google Scholar
• Benard VB, Castle PE, Jenison SA, et al. Population-based incidence rates of cervical intraepithelial neoplasia in the human papillomavirus vaccine era. JAMA Oncol. 2017;3(6):833–837.
   PubMed Web of Science ®Google Scholar
• Berenson AB, Hirth JM, Chang M. Change in human papillomavirus prevalence among U.S. women aged 18-59 years, 2009-2014. Obstet Gynecol. 2017;130(4):693–701.
   PubMed Web of Science ®Google Scholar
• Cocchio S, Baldovin T, Bertoncello C, et al. Decline in hospitalization for genital warts in the Veneto region after an HPV vaccination program: an observational study. BMC Infect Dis. 2017;17(1):249.
   PubMedGoogle Scholar
• Gargano JW, Unger ER, Liu G, et al. Prevalence of genital human papillomavirus in males, United States, 2013-2014. J Infect Dis. 2017;215(7):1070–1079.
   PubMed Web of Science ®Google Scholar
• Jacot-Guillarmod M, Pasquier J, Greub G, et al. Impact of HPV vaccination with Gardasil(R) in Switzerland. BMC Infect Dis. 2017;17(1):790.
   PubMedGoogle Scholar
• Lurie S, Mizrachi Y, Chodick G, et al. Impact of quadrivalent human papillomavirus vaccine on genital warts in an opportunistic vaccination structure. Gynecol Oncol. 2017;146(2):299–304.
   PubMed Web of Science ®Google Scholar
• Machalek DA, Chow EP, Garland SM, et al. Human papillomavirus prevalence in unvaccinated heterosexual men after a national female vaccination program. J Infect Dis. 2017;215(2):202–208.
   PubMed Web of Science ®Google Scholar
• Matsumoto K, Yaegashi N, Iwata T, et al. Early impact of the Japanese immunization program implemented before the HPV vaccination crisis. Int J Cancer. 2017;141(8):1704–1706.
   PubMed Web of Science ®Google Scholar
• Niccolai LM, Meek JI, Brackney M, et al. Declines in Human Papillomavirus (HPV)-associated high-grade cervical lesions after introduction of HPV vaccines in connecticut, United States, 2008-2015. Clin Infect Dis. 2017;65(6):884–889.
   PubMed Web of Science ®Google Scholar
• Oliphant J, Stewart J, Saxton P, et al. Trends in genital warts diagnoses in New Zealand five years following the quadrivalent human papillomavirus vaccine introduction. N Z Med J. 2017;130(1452):9–16.
   PubMed Web of Science ®Google Scholar
• Thone K, Horn J, Mikolajczyk R. Evaluation of vaccination herd immunity effects for anogenital warts in a low coverage setting with human papillomavirus vaccine-an interrupted time series analysis from 2005 to 2010 using health insurance data. BMC Infect Dis. 2017;17(1):564.
   PubMedGoogle Scholar
• Dillner J, Nygard M, Munk C, et al. Decline of HPV infections in Scandinavian cervical screening populations after introduction of HPV vaccination programs. Vaccine. 2018;36(26):3820–3829.
   PubMed Web of Science ®Google Scholar
• Flagg EW, Torrone EA. Declines in anogenital warts among age groups most likely to be impacted by human papillomavirus vaccination, United States, 2006-2014. Am J Public Health. 2018;108(1):112–119.
   PubMed Web of Science ®Google Scholar
• Guo F, Cofie LE, Berenson AB. Cervical cancer incidence in young U.S. females after human papillomavirus vaccine introduction. Am J Prev Med. 2018;55(2):197–204.
   PubMed Web of Science ®Google Scholar
• Herweijer E, Ploner A, Sparen P. Substantially reduced incidence of genital warts in women and men six years after HPV vaccine availability in Sweden. Vaccine. 2018;36(15):1917–1920.
   PubMed Web of Science ®Google Scholar
• Hirth J, McGrath CJ, Kuo YF, et al. Impact of human papillomavirus vaccination on racial/ethnic disparities in vaccine-type human papillomavirus prevalence among 14-26 year old females in the U.S. Vaccine. 2018;36(50):7682–7688.
   PubMed Web of Science ®Google Scholar
• Machalek DA, Garland SM, Brotherton JML, et al. Very low prevalence of vaccine human papillomavirus types among 18- to 35-year old australian women 9 years following implementation of vaccination. J Infect Dis. 2018;217(10):1590–1600.
   PubMed Web of Science ®Google Scholar
• McGregor S, Saulo D, Brotherton JML, et al. Decline in prevalence of human papillomavirus infection following vaccination among Australian Indigenous women, a population at higher risk of cervical cancer: the VIP-I study. Vaccine. 2018;36(29):4311–4316.
   PubMed Web of Science ®Google Scholar
• Novakovic D, Cheng ATL, Zurynski Y, et al. A prospective study of the incidence of Juvenile-Onset recurrent respiratory papillomatosis after implementation of a national HPV vaccination program. J Infect Dis. 2018;217(2):208–212.
   PubMed Web of Science ®Google Scholar
• Steben M, Ouhoummane N, Rodier C, et al. The early impact of human papillomavirus vaccination on anogenital warts in Quebec, Canada. J Med Virol. 2018;90(3):592–598.
   PubMed Web of Science ®Google Scholar
• Checchi M, Mesher D, Mohammed H, et al. Declines in anogenital warts diagnoses since the change in 2012 to use the quadrivalent HPV vaccine in England: data to end 2017. Sex Transm Infect. 2019;95(5):368–373.
   PubMed Web of Science ®Google Scholar
• Gargano JW, Park IU, Griffin MR, et al. Trends in high-grade cervical lesions and cervical cancer screening in 5 states, 2008-2015. Clin Infect Dis. 2019;68(8):1282–1291.
   PubMed Web of Science ®Google Scholar
• Karube A, Saito F, Nakamura E, et al. Reduction in HPV 16/18 prevalence among young women following HPV vaccine introduction in a highly vaccinated district, Japan, 2008-2017. J Rural Med. 2019;14(1):48–57.
   PubMedGoogle Scholar
• Mann LM, Llata E, Flagg EW, et al. Trends in the prevalence of anogenital warts among patients at sexually transmitted disease clinics-sexually transmitted disease surveillance network, United States, 2010-2016. J Infect Dis. 2019;219(9):1389–1397.
   PubMed Web of Science ®Google Scholar
• Markowitz LE, Naleway AL, Lewis RM, et al. Declines in HPV vaccine type prevalence in women screened for cervical cancer in the United States: evidence of direct and herd effects of vaccination. Vaccine. 2019;37(29):3918–3924.
   PubMed Web of Science ®Google Scholar
• McClung NM, Gargano JW, Bennett NM, et al. Trends in human papillomavirus vaccine types 16 and 18 in cervical precancers, 2008-2014. Cancer Epidemiol Biomarkers Prev. 2019;28(3):602–609.
   PubMed Web of Science ®Google Scholar
• McClung NM, Gargano JW, Park IU, et al. Estimated number of cases of high-grade cervical lesions diagnosed among women - United States, 2008 and 2016. MMWR Morb Mortal Wkly Rep. 2019;68(15):337–343.
   PubMed Web of Science ®Google Scholar
• McClung NM, Lewis RM, Gargano JW, et al. Declines in vaccine-type human papillomavirus prevalence in females across racial/ethnic groups: data from a national survey. J Adolesc Health. 2019;65(6):715–722.
   PubMed Web of Science ®Google Scholar
• Shing JZ, Hull PC, Zhu Y, et al. Trends in anogenital wart incidence among Tennessee Medicaid enrollees, 2006-2014: the impact of human papillomavirus vaccination. Papillomavirus Res. 2019;7:141–149.
   PubMed Web of Science ®Google Scholar
• Widdice LE, Bernstein DI, Franco EL, et al. Decline in vaccine-type human papillomavirus prevalence in young men from a Midwest metropolitan area of the United States over the six years after vaccine introduction. Vaccine. 2019;37(45):6832–6841.
   PubMed Web of Science ®Google Scholar
• Brackney MM, Gargano JW, Hannagan SE, et al. Human papillomavirus 16/18–associated cervical lesions: differences by area-based measures of race and poverty. Am J Prev Med. 2020;58:e149–e157.
   PubMed Web of Science ®Google Scholar
• Cleveland AA, Gargano JW, Park IU, et al. Cervical adenocarcinoma in situ: human papillomavirus types and incidence trends in five states, 2008-2015. Int J Cancer. 2020;146(3):810–818.
   PubMed Web of Science ®Google Scholar
• Naleway AL, Crane B, Smith N, et al. Temporal trends in the incidence of anogenital warts: impact of human papillomavirus vaccination. Sex Transm Dis. 2020;47(3):179–186.
   PubMed Web of Science ®Google Scholar
• Orumaa M, Kjaer SK, Dehlendorff C, et al. The impact of HPV multi-cohort vaccination: real-world evidence of faster control of HPV-related morbidity. Vaccine. 2020;38(6):1345–1351.
   PubMed Web of Science ®Google Scholar
• Oakley F, Desouki MM, Pemmaraju M, et al. Trends in high-grade cervical cancer precursors in the human papillomavirus vaccine era. Am J Prev Med. 2018;55(1):19–25.
   PubMed Web of Science ®Google Scholar
• Ogilvie GS, Naus M, Money DM, et al. Reduction in cervical intraepithelial neoplasia in young women in British Columbia after introduction of the HPV vaccine: an ecological analysis. Int J Cancer. 2015;137(8):1931–1937.
   PubMed Web of Science ®Google Scholar
• Robertson G, Robson SJ. Excisional treatment of cervical Dysplasia in Australia 2004-2013: a population-based study. J Oncol. 2016;2016:3056407.
   PubMed Web of Science ®Google Scholar
• Saadeh K, Park I, Gargano JW, et al. Prevalence of human papillomavirus (HPV)-vaccine types by race/ethnicity and sociodemographic factors in women with high-grade cervical intraepithelial neoplasia (CIN2/3/AIS), Alameda County, California, United States. Vaccine. 2020;38(1):39–45.
   PubMed Web of Science ®Google Scholar
• Ueda Y, Yagi A, Nakayama T, et al. Dynamic changes in Japan’s prevalence of abnormal findings in cervical cervical cytology depending on birth year. Sci Rep. 2018;8(1):5612.
   PubMed Web of Science ®Google Scholar
• Dominiak-Felden G, Gobbo C, Simondon F. Evaluating the early benefit of quadrivalent HPV vaccine on genital warts in Belgium: a cohort study. PLoS One. 2015;10(7):e0132404.
   PubMed Web of Science ®Google Scholar
• Grun N, Ahrlund-Richter A, Franzen J, et al. Oral human papillomavirus (HPV) prevalence in youth and cervical HPV prevalence in women attending a youth clinic in Sweden, a follow up-study 2013-2014 after gradual introduction of public HPV vaccination. Infect Dis (Lond). 2015;47(1):57–61.
   PubMed Web of Science ®Google Scholar
• Smith LM, Strumpf EC, Kaufman JS, et al. The early benefits of human papillomavirus vaccination on cervical dysplasia and anogenital warts. Pediatrics. 2015;135(5):e1131–40.
   PubMed Web of Science ®Google Scholar
• Kahn JA, Widdice LE, Ding L, et al. Substantial decline in vaccine-type Human Papillomavirus (HPV) among vaccinated young women during the first 8 years after HPV vaccine introduction in a community. Clin Infect Dis. 2016;63(10):1281–1287.
   PubMed Web of Science ®Google Scholar
• Chow EPF, Machalek DA, Tabrizi SN, et al. Quadrivalent vaccine-targeted human papillomavirus genotypes in heterosexual men after the Australian female human papillomavirus vaccination programme: a retrospective observational study. Lancet Infect Dis. 2017;17(1):68–77.
   PubMed Web of Science ®Google Scholar
• Oliver SE, Unger ER, Lewis R, et al. Prevalence of human papillomavirus among females after vaccine introduction-national health and nutrition examination survey, United States, 2003-2014. J Infect Dis. 2017;216(5):594–603.
   PubMed Web of Science ®Google Scholar
• Feiring B, Laake I, Christiansen IK, et al. Substantial decline in prevalence of vaccine-type and nonvaccine-type Human Papillomavirus (HPV) in vaccinated and unvaccinated girls 5 years after implementing HPV vaccine in Norway. J Infect Dis. 2018;218(12):1900–1910.
   PubMed Web of Science ®Google Scholar
• Innes CR, Sykes PH, Harker D, et al. Changes in human papillomavirus genotypes associated with cervical intraepithelial neoplasia grade 2 lesions in a cohort of young women (2013-2016). Papillomavirus Res. 2018;6:77–82.
   PubMed Web of Science ®Google Scholar
• Thamsborg LH, Napolitano G, Larsen LG, et al. Impact of HPV-vaccination on outcome of cervical cytology screening in Denmark - a register based cohort study. Int J Cancer. 2018;143:1662–1670.
   PubMed Web of Science ®Google Scholar
• Ährlund-Richter A, Cheng L, Hu YOO, et al. Changes in cervical Human Papillomavirus (HPV) prevalence at a youth clinic in Stockholm, Sweden, a decade after the introduction of the HPV vaccine. Front Cell Infect Microbiol. 2019;9:59.
   PubMed Web of Science ®Google Scholar
• Chow EPF, Tabrizi SN, Fairley CK, et al. Prevalence of human papillomavirus in teenage heterosexual males following the implementation of female and male school-based vaccination in Australia: 2014-2017. Vaccine. 2019;37(46):6907–6914.
   PubMed Web of Science ®Google Scholar
• Covert C, Ding L, Brown D, et al. Evidence for cross-protection but not type-replacement over the 11 years after human papillomavirus vaccine introduction. Hum Vaccin Immunother. 2019; 15 (7–8): ;1962–1969.
   PubMed Web of Science ®Google Scholar
• Hirth JM, Kuo YF, Starkey JM, et al. Regional variations in human papillomavirus prevalence across time in NHANES (2003-2014). Vaccine. 2019;37(30):4040–4046.
   PubMed Web of Science ®Google Scholar
• Matsumoto K, Yaegashi N, Iwata T, et al. Reduction in HPV16/18 prevalence among young women with high-grade cervical lesions following the Japanese HPV vaccination program. Cancer Sci. 2019;110(12):3811–3820.
   PubMed Web of Science ®Google Scholar
• Sarr EHM, Mayrand MH, Coutlee F, et al. Exploration of the effect of human papillomavirus (HPV) vaccination in a cohort of pregnant women in Montreal, 2010-2016. Heliyon. 2019;5(8):e02150.
   PubMed Web of Science ®Google Scholar
• Spinner C, Ding L, Bernstein DI, et al. Human papillomavirus vaccine effectiveness and herd protection in young women. Pediatrics. 2019;143:2.
   Web of Science ®Google Scholar
• Grove Krause T, Jakobsen S, Haarh M, et al. The Danish vaccination register. Euro Surveill. 2012;17:17.
   Google Scholar
• Machalek DA, Roberts JM, Garland SM, et al. Routine cervical screening by primary HPV testing: early findings in the renewed national cervical screening program. Med J Aust. 2019;211(3):113–119.
   PubMed Web of Science ®Google Scholar
• Lei J, Ploner A, Elfström KM, et al. HPV vaccination and the risk of invasive cervical cancer. N Engl J Med. 2020;383(14):1340–1348.
   PubMed Web of Science ®Google Scholar
• Veldhuijzen NJ, Snijders PJ, Reiss P, et al. Factors affecting transmission of mucosal human papillomavirus. Lancet Infect Dis. 2010;10(12):862–874.
   PubMed Web of Science ®Google Scholar
• Hanley SJ, Yoshioka E, Ito Y, et al. HPV vaccination crisis in Japan. Lancet. 2015;385(9987):2571.
   PubMed Web of Science ®Google Scholar
• Corcoran B, Clarke A, Barrett T. Rapid response to HPV vaccination crisis in Ireland. Lancet. 2018;391(10135):2103.
   PubMed Web of Science ®Google Scholar
• Suppli CH, Hansen ND, Rasmussen M, et al. Decline in HPV-vaccination uptake in Denmark - the association between HPV-related media coverage and HPV-vaccination. BMC Public Health. 2018;18(1):1360.
   PubMed Web of Science ®Google Scholar
• Simas C, Munoz N, Arregoces L, et al. HPV vaccine confidence and cases of mass psychogenic illness following immunization in Carmen de Bolivar, Colombia. Hum Vaccin Immunother. 2019;15(1):163–166.
   PubMed Web of Science ®Google Scholar
• Perry-Parrish C, Dodge R. Research and statistics: validity hierarchy for study design and study type. Pediatr Rev. 2010;31(1):27–29.
   PubMedGoogle Scholar
• Murad MH, Asi N, Alsawas M, et al. New evidence pyramid. Evid Based Med. 2016;21(4):125–127.
   PubMedGoogle Scholar
• European Centre for Disease Prevention and Control. Designing and implementing an immunisation information system. Stockholm (Sweden): European Centre for Disease Prevention and Control. Designing and implementing an immunisation information system. Stockholm; 2018.
   Google Scholar
• Vorsters A, Arbyn M, Baay M, et al. Overcoming barriers in HPV vaccination and screening programs. Papillomavirus Res. 2017;4:45–53.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Global strategy to accelerate the elimination of cervical cancer as a public health problem. 2020 Accessed 21 July 2021 Available from: https://www.who.int/publications/i/item/9789240014107.
   Google Scholar
• Arbyn M, Smith SB, Temin S, et al. Detecting cervical precancer and reaching underscreened women by using HPV testing on self samples: updated meta-analyses. BMJ. 2018;363:k4823.
   PubMedGoogle Scholar
• Van Keer S, Tjalma WAA, Pattyn J, et al. Human papillomavirus genotype and viral load agreement between paired first-void urine and clinician-collected cervical samples. Eur J Clin Microbiol Infect Dis. 2018;37(5):859–869.
   PubMed Web of Science ®Google Scholar
• Bissett SL, Howell-Jones R, Swift C, et al. Human papillomavirus genotype detection and viral load in paired genital and urine samples from both females and males. J Med Virol. 2011;83(10):1744–1751.
   PubMed Web of Science ®Google Scholar
• Koene F, Wolffs P, Brink A, et al. Comparison of urine samples and penile swabs for detection of human papillomavirus in HIV-negative Dutch men. Sex Transm Infect. 2016;92(6):467–469.
   PubMed Web of Science ®Google Scholar
• Söderlund-Strand A, Wikström A, Dillner J. Evaluation of human papillomavirus DNA detection in samples obtained for routine Chlamydia trachomatis screening. J Clin Virol. 2015;64:88–91.
   PubMed Web of Science ®Google Scholar
• Garland SM, Molesworth EG, Machalek DA, et al. How to best measure the effectiveness of male human papillomavirus vaccine programmes? Clin Microbiol Infect. 2015;21(9):834–841.
   PubMed Web of Science ®Google Scholar
• Jedy-Agba E, Joko WY, Liu B, et al. Trends in cervical cancer incidence in sub-Saharan Africa. Br J Cancer. 2020;123(1):148–154.
   PubMed Web of Science ®Google Scholar